Trial intelligence / Profile preview

Famitinib in previously treated advanced non-squamous NSCLC (phase II)

CTR20140850Phase 2Active

Sponsor
Hengrui Therapeutics
Start
Dec 2014
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of famitinib in Non-small cell lung cancer (NS-NSCLC), sponsored by Hengrui Therapeutics. Started Dec 2014; status: active.

02

Drugs

famitinib
03

Conditions

Non-small cell lung cancer (NS-NSCLC)

Beyond the preview

Go deeper on CTR20140850.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20140850.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call